Literature DB >> 21915800

Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.

Hyun-Il Cho1, Esteban Celis.   

Abstract

Plasmid DNA vaccination is an attractive way to elicit T cell responses against infectious agents and tumor cells. DNA constructs can be designed to contain multiple T cell epitopes to generate a diverse immune response to incorporate numerous antigens and to reduce limitations due to MHC restriction into a single entity. We have prepared cDNA plasmid constructs containing several mouse T cell epitopes connected by either furin-sensitive or furin-resistant linkers and studied the effects of a cationic cell-penetrating sequence from HIV-tat. Significant CD8 T cell responses were obtained with multi-epitope DNA vaccines followed by in vivo electroporation regardless of the type of linker used and whether the construct had the HIV-tat sequence. The magnitude of immune responses was very similar to all CD8 T cell epitopes contained within each vaccine construct, indicating the absence of immunodominance. Incorporating a T helper epitope into the constructs increased the T cell responses. Prophylactic and therapeutic antitumor responses against B16 melanoma were obtained using a construct containing epitopes from melanosomal proteins, indicating that this vaccination was successful in generating responses to self-antigens that potentially may be subjected to immune tolerance. These findings are useful for designing DNA vaccines for a multitude of diseases where T lymphocytes play a protective or therapeutic role.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21915800      PMCID: PMC4019994          DOI: 10.1007/s00262-011-1110-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines.

Authors:  B D Livingston; M Newman; C Crimi; D McKinney; R Chesnut; A Sette
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

2.  TAP-independent presentation of CTL epitopes by Trojan antigens.

Authors:  J Lu; P J Wettstein; Y Higashimoto; E Appella; E Celis
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

Review 3.  Design and development of synthetic peptide vaccines: past, present and future.

Authors:  Martijn S Bijker; Cornelis J M Melief; Rienk Offringa; Sjoerd H van der Burg
Journal:  Expert Rev Vaccines       Date:  2007-08       Impact factor: 5.217

Review 4.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

5.  Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.

Authors:  Stefan Tenzer; Edmund Wee; Anne Burgevin; Guillaume Stewart-Jones; Lone Friis; Kasper Lamberth; Chih-hao Chang; Mikkel Harndahl; Mirjana Weimershaus; Jan Gerstoft; Nadja Akkad; Paul Klenerman; Lars Fugger; E Yvonne Jones; Andrew J McMichael; Søren Buus; Hansjörg Schild; Peter van Endert; Astrid K N Iversen
Journal:  Nat Immunol       Date:  2009-05-03       Impact factor: 25.606

6.  Interferon γ limits the effectiveness of melanoma peptide vaccines.

Authors:  Hyun-Il Cho; Young-Ran Lee; Esteban Celis
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

7.  Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.

Authors:  Hyun-Il Cho; Esteban Celis
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

8.  In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.

Authors:  Deepak Assudani; Hyun-Il Cho; Nicholas DeVito; Norma Bradley; Esteban Celis
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

9.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance.

Authors:  Maya F Kotturi; Iain Scott; Tom Wolfe; Bjoern Peters; John Sidney; Hilde Cheroutre; Matthias G von Herrath; Michael J Buchmeier; Howard Grey; Alessandro Sette
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

View more
  9 in total

1.  Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.

Authors:  Paul D Bryson; Xiaolu Han; Norman Truong; Pin Wang
Journal:  Vaccine       Date:  2017-09-12       Impact factor: 3.641

2.  DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.

Authors:  Anna D Kosinska; Lena Johrden; Ejuan Zhang; Melanie Fiedler; Anja Mayer; Oliver Wildner; Mengji Lu; Michael Roggendorf
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

3.  DEC205-DC targeted DNA vaccines to CX3CR1 and CCL2 are potent and limit macrophage migration.

Authors:  Jimmy Jianheng Zhou; Yuan Min Wang; Vincent Ws Lee; Richard Ks Phoon; Geoff Yu Zhang; Ya Wang; Thian Kui Tan; Min Hu; Lucy Dongwei Wang; Mitsuru Saito; Andrew Sawyer; David C H Harris; Stephen I Alexander; Anne M Durkan
Journal:  Int J Clin Exp Med       Date:  2012-01-15

4.  Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes.

Authors:  S D Soysal; S Muenst; J Kan-Mitchell; E Huarte; X Zhang; I Wilkinson-Ryan; T Fleming; V Tiriveedhi; T Mohanakumar; L Li; J Herndon; D Oertli; S P Goedegebuure; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2014-09-12       Impact factor: 4.872

5.  Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.

Authors:  S Feola; C Capasso; M Fusciello; B Martins; S Tähtinen; M Medeot; S Carpi; F Frascaro; E Ylosmäki; K Peltonen; L Pastore; V Cerullo
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

6.  Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine.

Authors:  Negar Seyed; Tahereh Taheri; Charline Vauchy; Magalie Dosset; Yann Godet; Ali Eslamifar; Iraj Sharifi; Olivier Adotevi; Christophe Borg; Pierre Simon Rohrlich; Sima Rafati
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

7.  Expression and serological application of recombinant epitope-repeat protein carrying an immunodominant epitope of Newcastle disease virus nucleoprotein.

Authors:  Satish S Gaikwad; Hyun-Jeong Lee; Ji-Ye Kim; Kang-Seuk Choi
Journal:  Clin Exp Vaccine Res       Date:  2019-01-31

Review 8.  Post-Genomics and Vaccine Improvement for Leishmania.

Authors:  Negar Seyed; Tahereh Taheri; Sima Rafati
Journal:  Front Microbiol       Date:  2016-04-06       Impact factor: 5.640

9.  DEC205-DC targeted DNA vaccine against CX3CR1 protects against atherogenesis in mice.

Authors:  Jimmy Jianheng Zhou; Yuan Min Wang; Vincent W S Lee; Geoff Yu Zhang; Heather Medbury; Helen Williams; Ya Wang; Thian Kui Tan; David C H Harris; Stephen I Alexander; Anne M Durkan
Journal:  PLoS One       Date:  2018-04-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.